Different lysines on ubiquitin are involved in forming different ubiquitin chains, with K48-linked chains primarily signaling for proteasomal degradation, while other linkages, such as K63-linked chains, and single ubiquitin molecules (monoubiquitination) act as non-degradative signals for processes like DNA repair, signal transduction, and trafficking. Due to the diverse signaling and the multiple different lysines (K6, […]
The PA950 and PA770 are important assays for studying ubiquitination due to an E3 ligase or PROTAC, and the launch of the MG780 kit also extends this functionality to Molecular glues, opening up new options to test and verify functionality of compounds prior to later stage development, allowing ubiquitination to be confirmed which minimizes turnaround […]
MALVERN, Pa., October 26, 2023 — LifeSensors, Inc., a leading innovator in protein degradation technologies, has been invited to speak at the 6th Annual Targeted Protein Degradation Summit 2023 in Boston, Massachusetts. The event will take place from October 30-November 2 at Westin Copley Place, Boston. LifeSensors will be exhibiting, and Dr. Karteek Kadimisetty will […]
[Malvern, PA, October 18, 2023] — LifeSensors Inc., a biotech company targeting the ubiquitin proteasome system for drug discovery and diagnostic markers, has received funding from the National Institute on Aging and National Institute of General Medicine. The funding, to the tune of $5.53 million, provides for the development of PROTAC drug discovery technologies. PROTACs […]
MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the 21st annual Discovery on Target 2023. Dr. Karteek Kadimisetty, LifeSensors’ Director of Research and Development will be presenting new information, and answering questions regarding PROTACs, […]
By: Isabelle Wentzel Devastating Origins In the late 1950s and early 1960s, pregnant women who experienced nausea and morning sickness were prescribed thalidomide, a sedative drug meant to treat these symptoms. In early 1960, it quickly became evident that there was a link between the thousands of infants born with severe birth defects and […]
UbiTest: Detection of polyubiquitinated proteins using TUBE based screening platforms by Gauthami S. Jalagadugula The ubiquitin proteasome system (UPS) is a highly regulated mechanism that controls many cellular processes through protein ubiquitination and degradation. Ubiquitin is conjugated via its C-terminus to lysine residues on the target proteins as a monomer or as a polymer chain. […]
Hijacking the natural mechanism of the Ubiquitin Proteasome System (UPS) is emerging as a powerful medium in drug discovery through which Dr. Kadimisetty uses “TUBEs” as ubiquitin-binding entities to monitor PROTAC-mediated poly-ubiquitination of target proteins. The technology described wherein is a direct way to evaluate and discover PROTAC and molecular glue targets for use in […]
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein degradation Gauthami Jalagadugula, Alexandra Russell1+, Kenneth Wallace1+, Janelle Pedroza and Abdul Haseeb1 * Introduction PROteolytic TArgeting Chimeras (PROTACs) have emerged as new class of drugs to target “undruggable” proteome. The human genome encodes ~ 600 E3 ligases that differentially expressed across various tissues. Only a […]
PROTACs and Molecular Glues: High-Throughput Quantitative Assays for Rationale Design Authors: Janelle Pedroza1, Kenneth Wallace1, Derrick Padykula, Alexandra Russell1, and Karteek Kadimisetty*1 Introduction PROTACs have emerged as new class of drugs that can target the “undruggable” proteome by hijacking the ubiquitin proteasome system. Traditional methods like western blotting and reporter gene assays are prone to […]
MALVERN, Pa., SEP 1, 2022 – LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glues, and neurodegeneration diagnostics, is pleased to announce that Lifesensors has published a seminal paper: Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. This paper is published in the Biochemical and Biophysical […]
SEE THE LIFESENSORS PRESENTATION ON NOVEL PROTAC ASSAYS HERE. PLEASE CONTACT US FOR MORE INFORMATION ON THIS EXCITING TECHNOLOGY- BD@LIFESENSORS.COM
